Since CXCL10 is regulated by TLR3 and is suggested to mediate TLR3-related inflammatory responses in RA [148], there is potential for the development of TLR3 antagonists as therapeutic options for autoimmune diseases in the future. This evidence concerns the gene TLR3 and autoimmune disease.